Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancyStuart Thomson(Bioscience Research), John D. Haley(Stony Brook University)Clinical & Experimental MetastasisAugust 11, 200810.1007/s10585-008-9200-4Cited by 192SaveCiteExport RISWatch citationsRelated PapersPhosphotyrosine Signaling Networks in Epidermal Growth Factor Receptor Overexpressing Squamous Carcinoma Cells|Molecular & Cellular Proteomics|2005|134Mass Spectrometry and Pharmacological Approaches to Measuring Cooption and Reciprocal Activation of Receptor Tyrosine Kinases|Proteomes|2023|2